Call Us: US - +1 845 478 5244 | UK - +44 20 7193 7850 | AUS - +61 2 8005 4826

“Molecular genetic analysis of Down syndrome”.

DNA-based noninvasive prenatal tests of fetal aneuploidy are proven and/or medically necessary as screening tools for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) or trisomy 13 (Patau syndrome) in ANY ONE of the following circumstances:  Maternal age of 35 years or older at delivery  Fetal ultrasound findings indicating an increased risk of aneuploidy  History of a prior pregnancy with a trisomy  Positive first- or second-trimester screening test results for aneuploidy  Parental balanced Robertsonian translocation with an increased risk of fetal trisomy 13 or trisomy 21 DNA-based noninvasive prenatal tests of fetal aneuploidy are unproven and/or not medically necessary for all other indications including, but not limited to, the following:  Multiple gestation pregnancies  Screening for microdeletions  Screening for sex chromosome aneuploidies Further studies are needed to evaluate the use of these tests in other populations. Genetic Counseling Genetic counseling is strongly recommended prior to this test in order to inform persons being tested about the advantages and limitations of the test as applied to a unique person.